Provided by Tiger Trade Technology Pte. Ltd.

Zevra Therapeutics

11.74
+0.17501.51%
Post-market: 11.71-0.0300-0.26%19:59 EDT
Volume:818.90K
Turnover:9.56M
Market Cap:694.01M
PE:12.23
High:11.81
Open:11.56
Low:11.39
Close:11.57
52wk High:15.04
52wk Low:7.16
Shares:59.11M
Float Shares:53.86M
Volume Ratio:1.20
T/O Rate:1.52%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.9602
EPS(LYR):1.35
ROE:34.80%
ROA:8.74%
PB:3.19
PE(LYR):8.70

Loading ...

Zevra Therapeutics Schedules Q2 Earnings Call

Reuters
·
Jul 22

Zevra Therapeutics (ZVRA) Following Russell Index Additions Is The Stock Still Undervalued

Simply Wall St.
·
Jul 02

Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), BeOne Medicines (ONC) and Zevra Therapeutics (ZVRA)

TIPRANKS
·
Jul 01

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 24

Zevra Therapeutics Chief Legal & Compliance Rahsaan Thompson sells 34,557 shares for $438,216.86

Reuters
·
Jun 24

Zevra Therapeutics Price Target Maintained With a $26.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 24

Zevra Therapeutics: New Infant MIPLYFFA Data Reinforce Core NPC Role; Buy Rating and $26 Price Target Reiterated

TIPRANKS
·
Jun 23

Zevra publishes Miplyffa data in Molecular Genetics, Metabolism Reports

TIPRANKS
·
Jun 23

Zevra publishes Phase 2/3 pediatric substudy showing MIPLYFFA tolerability in infants with Niemann-Pick type C

Reuters
·
Jun 23

Zevra Therapeutics chief medical officer to step down

TIPRANKS
·
Jun 11

Zevra Therapeutics CMO Adrian Quartel to step down July 3 for personal reasons

Reuters
·
Jun 11

Zevra’s Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition

THOMSON REUTERS
·
Jun 11

Press Release: Zevra's Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition

Dow Jones
·
Jun 11

Zevra Therapeutics Is Maintained at Buy by Maxim Group

Dow Jones
·
Jun 11

Zevra Therapeutics price target raised to $35 from $25 at Maxim

TIPRANKS
·
Jun 11

A Look At Zevra Therapeutics (ZVRA) Valuation As MIPLYFFA Patent Extension Targets 2041 Exclusivity

Simply Wall St.
·
Jun 10

Analysts Are Bullish on These Healthcare Stocks: Zevra Therapeutics (ZVRA), Alpha Cognition Inc (ACOG)

TIPRANKS
·
Jun 10

Zevra Therapeutics price target raised to $27 from $23 at BTIG

TIPRANKS
·
Jun 10

Zevra Therapeutics Is Maintained at Market Outperform by Citizens

Dow Jones
·
Jun 09

Does Zevra Therapeutics (ZVRA) Patent Push and Board Structure Signal a Shifting Risk Profile?

Simply Wall St.
·
Jun 09